Inovio Pharmaceuticals, Inc.(INO) stock price and fundamentals

Biotechnology · Plymouth Meeting, PA

$1.13-0.02 (-1.74%)

Delayed quote: Oct 6, 2026, 1:50 PM EDT

About Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.

Plymouth Meeting, PA

112 employees

www.inovio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jacqueline E. Shea

View full financials

Stock	Market Cap	Close Price	Price Change	TTM Total Return	5Y CAGR	10Y CAGR	Compare
1INO	$78.07M	$1.13	-1.74%	-52.51%	-57.05%	-36.78%	N/A
2NTHI	$78.05M	$3.01	+3.08%	-74.51%	N/A	N/A	vs INO
3SERA	$77.15M	$2.02	+1.00%	-38.32%	-28.91%	N/A	vs INO
4LUNG	$77.08M	$1.82	-2.93%	+2.16%	-45.30%	N/A	vs INO
5OM	$76.56M	$4.13	+0.73%	-71.53%	-64.47%	N/A	vs INO
6HYPR	$76.48M	$0.91	+2.85%	-40.20%	-38.34%	N/A	vs INO

Period	Low	Avg	High	# Analysts
Quarter ending Sep 2026	$-0.20	$-0.20	$-0.19	2
Quarter ending Dec 2026	$-0.18	$-0.18	$-0.18	2
Quarter ending Mar 2027	$-0.17	$-0.17	$-0.17	1
Quarter ending Jun 2027	$-0.13	$-0.13	$-0.13	1

Period	Low	Avg	High	# Analysts
FY 2026	$-0.77	$-0.76	$-0.75	2
FY 2027	$-0.65	$-0.43	$-0.20	2

Period	Low	Avg	High	# Analysts
Quarter ending Sep 2026	$2.27M	$2.27M	$2.27M	2
Quarter ending Dec 2026	$666667.00	$666667.00	$666667.00	2
Quarter ending Mar 2027	$6.90M	$6.90M	$6.90M	1
Quarter ending Jun 2027	$14.10M	$14.10M	$14.10M	1

FY 2026	$416331.00	$666667.00	$873877.00	2
FY 2027	$36.71M	$50.60M	$64.49M	2

Inovio Pharmaceuticals, Inc.(INO) stock price and fundamentals

Valuation

INO Price Chart

Business at a glance

INO is featured in

INO Key Metrics

Total Return CAGR

INO Fundamental Charts

Revenue CAGR

INO Selected Revenue Disclosures

Product / business disclosures (FY 2025)

INO Earnings Preview

Similar-Size Sector Stocks

INO Competitors' Key Metrics

INO Charts

Valuation Charts

Performance Charts

Dividend Charts

CAGR Charts

Financial Statement Charts

Other Charts

INO Analyst Ratings

INO Analyst Estimates

Earnings Per Share (EPS) Estimates

Revenue Estimates